RLYB
Rallybio Corp
NASDAQ · Healthcare · Biotechnology · US
$15.90
+0.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$15.53
From 52W high−7.67%
Volume59239.00
Market cap$85.60M
P/E (TTM)3.4x
P/S (TTM)197.2x
Div yield—
Key dataNov 4, 2026
Open
$15.53
From 52W high
−7.67%
Volume
59239.00
Market cap
$85.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
3.4x
RSI (14)
42.7
MomentumView details →
1D Return
+0.25%
YTD Return
+190.53%
SummaryUpdated Sep 1, 2026
Rallybio Corporation (NASDAQ:RLYB) is a clinical-stage biotechnology company founded in 2018 and headquartered in New Haven, Connecticut. The company went public in July 2021 and focuses on discovering, developing, manufacturing, and delivering therapies for patients suffering from severe and rare diseases. Since its founding, Rallybio has concentrated its efforts on developing innovative treatments for conditions with significant unmet medical needs, particularly in areas where current therapeutic options are limited or nonexistent.
Similar companies
Latest newsMore news →